

EVALUATION OF SERUM IL-23 LEVEL IN ACTIVE, STABLE AND NARROW BAND ULTRAVIOLET B TREATED VITILIGO

Thesis

*Submitted For Partial Fulfillment of Master Degree in
Dermatology, Venereology and Andrology*

By

Omar Ala Dawod

M. B. Ch. B.

Baghdad University

Under Supervision of

Prof Dr. Mohamed Abd El-Rahim Abdallah

*Professor of Dermatology, Venereology and Andrology
Faculty of Medicine - Ain Shams University*

Prof. Dr Ghada Fathy Mohamad

*Professor of Dermatology, Venereology and Andrology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine - Ain Shams University

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

First, and foremost, my deepest gratitude and thanks should be offered to "ALLAH", the Most Kind and Most Merciful, for giving me the strength to complete this work.

I would like to express my sincere gratitude to Prof. Dr. Mohamed abd El-Rahim Abdalla, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine -Ain Shams University, for his continuous support and guidance for me to present this work. It really has been an honor to work under his generous supervision.

I acknowledge with much gratitude to Prof. Dr. Ghada Fathy Mohamad, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine-Ain Shams University for her efforts and time she has devoted for this work.

Last but not least, thanks to my Family and especially my great wife for helping me to finish this work.

Omar Ala Dawod

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	10
Introduction	1
Aim of the Work.....	16
Review of Literature	
▪ Vitiligo	17
▪ Narrow Band UVB	59
▪ Interleukine-23 (IL-23)	75
Patients and Methods	88
Results	98
Discussion	123
Summary	128
Conclusion	131
Recommendations	132
References	133
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Typical Features of Segmental and Nonsegmental Vitiligo.....	27
Table (2):	Vitiligo disease activity score (VIDA)	53
Table (3):	List of depigmenting agents	57
Table (4):	Degree of erythema Dose increment.....	66
Table (5):	Skin types/ initial NB-UVB dose according to skin type	67
Table (6):	Contraindications of NB-UVB.....	71
Table (7):	Human studies examining IL-17 biomarkers in vitiligo	84
Table (8):	Biologic drugs targeting IL-23 and IL-17 in psoriasis.....	87
Table (9):	Comparison between patients and controls as regards age.	99
Table (10):	Comparison between patients with active and stable vitiligo as regards age.....	100
Table (11):	Comparison between patients with active and stable vitiligo with the control group as regards sex.....	101
Table (12):	Comparison between males and females patients as regards S. IL-23 before NB-UVB treatment.	102
Table (13):	Comparison between levels of S.IL-23 before and after NB-UVB treatment in all patients (active +stable).....	104
Table (14):	Comparison between the patient group (active + stable) and control group before NB-UVB treatment as regards S. IL-23 level.....	106
Table (15):	Comparison between patients with active and stable vitiligo as regards serum IL-23 level before NB:UVB.	107

List of Tables (cont...)

Table No.	Title	Page No.
Table (16):	Comparison between levels of S. IL-23 before and after NB-UVB treatment in active vitiligo group.	109
Table (17):	Comparison between the levels of S. IL-23 in stable and NB-UVB treated vitiligo.....	111
Table (18):	Comparison between patients with active vitiligo and controls as regards serum IL-23 level before NB-UVB treatment.	113
Table (19):	Comparison between patients with stable vitiligo and controls as regards serum IL-23 level.	115
Table (20):	Comparison between patients with active vitiligo and controls as regards serum IL-23 level after NB-UVB treatment.....	117
Table (21):	Comparison between (VETI) score before versus after NB-UVB treatment in all patients (active+ stable).....	118
Table (22):	Comparison between (VETI) score before versus after NB-UVB treatment in patients with stable vitiligo.....	119
Table (23):	Comparison between (VETI) score before versus after NB-UVB treatment in patients with active vitiligo.....	120
Table (24):	Correlation of age, disease duration and VETI score with serum IL-23 level before NB-UVB treatment in all patients.....	122

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Inflammatory vitiligo	22
Figure (2):	Vitiligo ponctué. Confetti-like amelanotic macules	22
Figure (3):	Differentiation of T helper cell subsets	36
Figure (4):	Summary of the possible cellular and humoral immune mechanisms of vitiligo	37
Figure (5):	Hypopigmentation (including trichrome, and homogeneous lighter pigmentation)	44
Figure (6):	Complete depigmentation with black hair and perifollicular pigmentation	44
Figure (7):	Complete depigmentation with black hair and without perifollicular pigmentation.....	45
Figure (8):	Complete depigmentation with compound of white and black hair with/without perifollicular pigmentation	45
Figure (9):	Complete depigmentation plus significant hair whitening.....	46
Figure (10):	Depth of skin penetration of UV, visible and infrared radiations	60
Figure (11):	Schematic illustration of the IL-12 and IL-23 receptor complexes.....	78
Figure (12):	Predicted site-I-II-III paradigm and experimentally validated model of the IL-23 receptor complex	78
Figure (13):	Divergent but overlapping functions of IL-23 in different models of autoimmunity.....	81
Figure (14):	Schematic representation of the mechanisms by which IL-23 indirectly or directly promotes tumorigenesis, growth and metastasis	82

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (15):	Rule of nine.....	96
Figure (16):	Comparison between patients and controls as regards age.	99
Figure (17):	Comparison between patients with active and stable vitiligo as regards age.....	100
Figure (18):	Comparison between patients with active and stable vitiligo with the control group as regards sex.....	102
Figure (19):	Comparison between levels of S.IL-23 before versus after NB-UVB treatment in all patients (active+stable).....	104
Figure (20):	Comparison between the patient group (active + stable) and control group before NB-UVB treatment as regards S. IL-23 level.	106
Figure (21):	Comparison between patients with active and stable vitiligo as regards serum IL-23 level before NB:UVB.....	107
Figure (22):	Comparison between levels of S. IL-23 before and after NB-UVB treatment in active vitiligo group.	109
Figure (23):	Comparison between the levels of S. IL-23 in stable and NB-UVB treated vitiligo.....	111
Figure (24):	Comparison between patients with active vitiligo and controls as regards serum IL-23 level before NB:UVB treatment.	113
Figure (25):	Comparison between patients with stable vitiligo and controls as regard serum IL-23 level.....	115

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (26):	Comparison between patients with active vitiligo and controls as regards serum IL-23 level after NB-UVB treatment	117
Figure (27):	Comparison between (VETI) score before versus after NB-UVB treatment in all patients (active+ stable).	118
Figure (28):	Comparison between (VETI) score before versus after NB-UVB treatment in patients with stable vitiligo.	119
Figure (29):	Comparison between (VETI) score before versus after NB-UVB treatment in patients with active vitiligo.	120
Figure (30):	Correlation of serum IL-23 level with VETI score before NB-UVB treatment.....	122

List of Abbreviations

Abb.	Full term
AA	<i>Arachidonic acid</i>
ACE	<i>Angiotensin – Converting Enzyme</i>
AHA	<i>American heart association</i>
AICAR	<i>Aminoimidazole -4- carboxamide ribonucleotide</i>
AIDS	<i>Acquired immunodeficiency syndrome</i>
AMPK	<i>Adenosine monophosphate kinase</i>
AMPs	<i>Antimicrobial peptides</i>
AP-1	<i>Activator protein -1</i>
APCs	<i>Antigen presenting cells</i>
AS	<i>Ankylosing spondylitis</i>
BAT	<i>Brown adipose tissue</i>
BCG	<i>Balillus Calmette-Guerin</i>
BMI	<i>Body mass index</i>
BP	<i>Blood pressure</i>
BSA	<i>Body surface area</i>
CB-1	<i>Cannabinoid-1 receptor</i>
CBD	<i>Cytokine binding domains</i>
CD	<i>Cluster of differentiation</i>
CVD	<i>Cardiovascular disease</i>
DCs	<i>Dendritic cells</i>
DLQI	<i>Dermatology Life Quality Index</i>
DM	<i>Diabetes Mellitus</i>
DPP	<i>Diabetes prevention program</i>
EAE	<i>Experimental autoimmune encephalomyelitis</i>
EDTA	<i>Ethylene diamine tetra-acetic acid</i>
EGF	<i>Epidermal growth factor</i>
EGF-R	<i>Epidermal growth factor receptor</i>
ELISA	<i>Enzyme linked immunosorbant assay</i>
GBP-28	<i>Gelatin binding protein-28</i>

List of Abbreviations (cont...)

Abb.	Full term
GLUT4	<i>Glucose transporter type 4</i>
GM-CSF	<i>Granulocyte macrophage colony stimulating factor</i>
HDL	<i>High density lipoprotein</i>
HEV	<i>High Endothelial Venules</i>
HIV	<i>Human Immunodeficiency Virus</i>
HMW	<i>High molecular weight</i>
IBD	<i>Inflammatory bowel disease</i>
ICAM	<i>Intercellular adhesion molecule</i>
Ig	<i>Immune globulin</i>
IGF-1	<i>Insulin growth factor-1</i>
IGT	<i>Impaired glucose tolerance</i>
IL	<i>Interleukin</i>
ILs	<i>Interleukins</i>
INF	<i>Interferon</i>
iNOS	<i>Inducible nitric oxide synthase</i>
IR	<i>Insulin resistance</i>
kDa	<i>Kilo Dalton</i>
LC	<i>Langerhans' cell</i>
LCAT	<i>Lecithin cholesterol acyltransferase</i>
LDL	<i>Low density lipoprotein</i>
LFA	<i>Lymphocyte functional antigen</i>
LPS	<i>Lipopolysaccharide</i>
LT	<i>Leukotriens</i>
MCA	<i>Methyl cholanthrene-A</i>
MCP-1	<i>Monocyte chemotactic protein-1</i>
MDA	<i>Malondialdehyde</i>
MHC	<i>Major histocompatibility complex</i>
MITF	<i>Microphthalmia-associated transcription factor</i>
MMPs	<i>Matrix metalloproteinases</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>mRNA</i>	<i>Messenger ribonucleic acid</i>
<i>MS</i>	<i>Metabolic syndrome</i>
<i>MTX</i>	<i>Methotrexate</i>
<i>NCEP</i>	<i>National cholesterol education program</i>
<i>NF-AT</i>	<i>Nuclear factor of activated T cell</i>
<i>NF-κB</i>	<i>Nuclear Factor- κB</i>
<i>NGF</i>	<i>Nerve growth factor</i>
<i>NK</i>	<i>Natural killer</i>
<i>NO</i>	<i>Nitric oxide</i>
<i>NSAIDS</i> ...	<i>Non-Steroidal Anti-inflammatory Drugs</i>
<i>PAI-1</i>	<i>Plasminogen activator inhibitor-1</i>
<i>PASI</i>	<i>Psoriasis area and severity index</i>
<i>PGA</i>	<i>Physician Global Assessment</i>
<i>PLE</i>	<i>Polymorphic light eruption</i>
<i>PPAR</i>	<i>Peroxisome proliferator- activated receptor</i>
<i>PsA</i>	<i>Psoriatic arthritis</i>
<i>PSORS</i>	<i>Psoriasis Susceptibility</i>
<i>PUVA</i>	<i>Psoralen + UVA</i>
<i>RA</i>	<i>Rheumatoid arthritis</i>
<i>Scf</i>	<i>Stem cell factor</i>
<i>SOD</i>	<i>Superoxide Dismutase</i>
<i>SP</i>	<i>Substance P</i>
<i>T regs</i>	<i>T regulatory cells</i>
<i>TACE</i>	<i>TNFα convertase enzyme</i>
<i>TAS</i>	<i>Total Antioxidant Status</i>
<i>Tc-1</i>	<i>T cytotoxic -1</i>
<i>TCR</i>	<i>T cell receptor</i>
<i>TG</i>	<i>Triglycerides</i>
<i>TGF-β</i>	<i>Transforming growth factor-β</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>Th</i>	<i>T-helper</i>
<i>TLR</i>	<i>Toll like receptor</i>
<i>TNFR</i>	<i>Tumor necrosis factor receptor</i>
<i>TNFSF</i>	<i>Tumor necrosis factor superfamily</i>
<i>TNF-α</i>	<i>Tumor necrosis factor-alpha</i>
<i>TZD</i>	<i>Thiazolidinedione</i>
<i>UVA</i>	<i>Ultraviolet A</i>
<i>UVB</i>	<i>Ultraviolet B</i>
<i>VASI</i>	<i>Vitiligo area scoring index</i>
<i>VCAM</i>	<i>Vascular cell adhesion molecule</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>
<i>VIDA</i>	<i>Vitiligo disease activity score</i>
<i>VIP</i>	<i>Vasoactive intestinal peptide</i>
<i>vit</i>	<i>Vitiligo</i>
<i>VPF</i>	<i>Vascular permeability factor</i>
<i>WAT</i>	<i>White adipose tissue</i>
<i>WC</i>	<i>Waist circumference</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

Vitiligo is an acquired depigmentary disorder characterized by the loss of functioning epidermal melanocytes and affects more than 0.5–1% of the worldwide population with devastating psychological and social consequences (*Feily, 2014*). The exact pathologic mechanism has not been clarified yet; however, the autoimmune hypothesis is the most widely accepted explanation (*Shin et al., 2010*).

Vitiligo has been classified according to the clinical ground into two major forms, namely segmental vitiligo (S.V.) and non-segmental vitiligo (N.S.V.), the latter includes several variants (generalized, acro facial and universal), non segmental vitiligo typically evolves over time in both distribution and extension patterns (*Taieb and Picardo, 2007*).

Peripheral blood and skin biopsies of patients with vitiligo showed that T cells, mononuclear cells, pro-inflammatory cytokines and autoanti bodies can damage melanocytes (*Sandoval-Cruz et al., 2011*). Peripheral lesional cytotoxic T cells seem to be responsible for the depigmentation process which may produce targeted autoimmune tissue destruction (*Zamani et al., 2001*).

A significant change of epidermal cytokines in involved skin of patients with vitiligo compared with uninvolved skin and skin of healthy controls has been described (*Kim et al.,*

2011), among these proinflammatory cytokines is IL-23 which is a member of IL-12 family that activates the effector function of T helper 17 (TH 17) cells to promote the inflammatory responses, this cytokine induces the production of TH17 cells so it was thought that it mediates autoimmunity by secretion of IL17 family, it has been established that IL-23 is essential for the development of autoimmune diseases, including psoriatic skin inflammation, inflammatory bowel diseases auto immune diabetes and others (*Croxford et al., 2012*).

In patients with vitiligo increased levels of IL-17 (which is mediated by IL-23) in serum was observed suggesting that IL-17 is participating in the immune response in early onset of the disease (*Duvallet et al., 2011*), for this reason IL-23/TH-17 was considered as a relevant target in treatment of auto immune diseases and the biological agents blocking IL-23 or IL-17 are currently being developed, Ustekinumab is a mono clonal anti body targeting the common P40 subunit of IL-23 and IL-12 (*Toussiro, 2012*).

Phototherapy is the therapeutic use of ultraviolet irradiation without exogenous photosensitizer (*Rai and Srinivas, 2007*).

It is thought that its capability to induce T cell apoptosis is an indicator of clinical efficacy, furthermore, keratinocytes may be influenced to release other unidentified cytokines and factors, which suggests that UVB functions as an immune modulator, which may support the theory of autoimmune component in the pathogenesis of vitiligo (*Noborio et al., 2006*).